![]() |
Trials |
An open-label, phase 2 study of neratinib in patients with solid tumors with somatic human epidermal growth factor receptor (EGFR, HER2, HER3) mutations or EGFR gene amplificationCancer type: Solide tumores Phase: II Principal Investigator: Joensuu Heikki Country: FI Keywords: Helsinki, Finland Status: Open for inclusion Link to Clinicaltrials.gov: http://clinicaltrials.gov/ct2/show/NCT01953926 |